Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma

Panobinostat is a pan‐deacetylase inhibitor that modulates the expression of oncogenic and immune‐mediating genes involved in tumour cell growth and survival. We evaluated panobinostat‐induced post‐transplant responses and identified correlative biomarkers in patients with multiple myeloma who had f...

Descripción completa

Detalles Bibliográficos
Autores principales: Mithraprabhu, Sridurga, Kalff, Anna, Gartlan, Kate H., Savvidou, Ioanna, Khong, Tiffany, Ramachandran, Malarmathy, Cooke, Rachel E., Bowen, Kathryn, Hill, Geoffrey R., Reynolds, John, Spencer, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048685/
https://www.ncbi.nlm.nih.gov/pubmed/32945549
http://dx.doi.org/10.1111/bjh.17080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048685/
https://www.ncbi.nlm.nih.gov/pubmed/32945549
http://dx.doi.org/10.1111/bjh.17080

Ejemplares similares